GW7647 NEW
| Price | $45 | $98 | $150 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-15 |
Product Details
| Product Name: GW7647 | CAS No.: 265129-71-3 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2026/06/15 |
Product Introduction
Bioactivity
| Name | GW7647 |
| Description | GW 7647 is an effective and highly selective PPARα agonist, the EC 50 values of human PPARα, PPARγ and PPARδ receptors are 6,1100 and 6200 nM, respectively. GW 7647 can reduce the production of nitric oxide in macrophages and has lipid-lowering and anti-inflammatory properties in the body. |
| In vitro | GW7647 at a concentration of 50 nM, promotes PI3K and Akt (Ser473) phosphorylation, leading to an increase in NOS1 phosphorylation and subsequently elevating NO levels in stripped antral mucosa. Additionally, at the same concentration, it boosts the initial phase of Ca2+-mediated exocytotic events triggered by ACh in antral mucous cells, without independently inducing any exocytotic events. At a higher concentration of 1 μM, GW7647 substantially elevates PDZK1 protein levels to 129.7 ± 6.5% compared to controls in Caco2BBE cells, irrespective of IL-1β presence, and mitigates the IL-1β-induced reduction in PDZK1 expression. When combined with ACh, GW7647 augments the impact of wortmannin (50 nM) and AKT-inh (100 nM) on exocytotic activity in these cells. At 100 nM, GW7647 significantly decreases AQP9 protein levels by 43% in WIF-B9 hepatocytes and by 24% in HepG2 cells, though it shows no notable effects at 10 and 1,000 nM in WIF-B9 hepatocytes, nor does it significantly affect L-FABP protein levels in HepG2 hepatocytes. |
| In vivo | GW7647 (3 mg/kg per day) does not prevent cardiac hypertrophy but preserves left ventricular ejection fraction in vivo [4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.98 mM), Sonication is recommended. DMSO : 81.67 mg/mL (162.45 mM), Sonication is recommended. |
| Keywords | PPARδ | PPARγ | PPARα | PPAR | Peroxisome proliferator-activated receptors | Inhibitor | inhibit | GW-7647 | GW7647 | GW 7647 |
| Inhibitors Related | PHYTOL | Rosiglitazone | Retinoic acid | Daidzein | Fenofibrate | Magnesium acetate tetrahydrate | Maltitol | Naringenin | 2,3-Butanediol | NPC 15199 | Icariin | Cloxiquine |
| Related Compound Libraries | Ferroptosis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Anti-Obesity Compound Library | Anti-Breast Cancer Compound Library | Mitochondria-Targeted Compound Library | Lipid Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Hypertension Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY